Takeda and Iambic ink $1.7 B deal to advance AI driven design of small molecules

11 February 2026 | News

Multi-year partnership will utilise Iambic's broad suite of AI drug discovery technologies and wet lab capabilities

Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.

Through the agreement, Takeda will also gain access to NeuralPLexer, Iambic's industry leading model for predicting protein-ligand complexes.

Under the terms of the agreement, Iambic will receive upfront, research cost, and technology access payments and is eligible to receive success-based payments that could exceed $1.7 billion. The company is also eligible to receive royalties on net sales of any products generated from this collaboration.

The collaboration will utilise Iambic's AI models as well as the company's fully integrated, high-throughput, and automated wet lab capabilities. These core capabilities support a rapid Design-Make-Test-Analyze cycle that can accelerate programme advancement.